Ascletis Pharmaceuticals Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist

This Ascletis Pharmaceuticals Co., Ltd. Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP establishes pipeline ownership and stage, reconstructs transaction precedents and surfaces financial signals; Current Awareness MCP adds recent events and outreach clues. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions where returned. This is a screening memorandum, not legal, medical, patent or investment advice.

Executive BD screen

Ascletis Pharmaceuticals Co., Ltd. returned 38 pipeline records in the organization search. The near-term screen centers on Ravidasvir Hydrochloride, reported at Approved, with ownership attributed to Ascletis Pharma, Inc.; Ascletis BioScience Co., Ltd.; Ascletis Pharmaceuticals Co., Ltd.. The Ascletis Pharmaceuticals Co., Ltd. official organization website passed the external-link verification gate; ownership still requires confirmation against current corporate and asset records.

The practical partnering thesis is to qualify the current owner, validate the evidence package behind the next development milestone, and determine whether geography, indication, combination, manufacturing or option rights remain available. The shortlist below is prioritized by returned maturity rather than an unverified probability-of-success score.

Partnering shortlist

Owner caution: returned owner names include Ascletis Pharma, Inc.; Ascletis BioScience Co., Ltd.; Ascletis Pharmaceuticals Co., Ltd.. Confirm legal entity, chain of title, encumbrances and sublicensing authority before relying on the owner field.

Evidence package to request

• Clinical: protocol, statistical analysis plan, patient-level disposition, efficacy tables, safety narratives, biomarker plan and regulator correspondence for Ravidasvir Hydrochloride.
• Translational: target engagement, dose–exposure–response, model relevance, resistance hypotheses and differentiation versus current standard of care.
• CMC: process description, specifications, comparability history, stability, scale-up assumptions, critical suppliers and cost-of-goods model.
• Commercial: target product profile, addressable segments, competitive trials, pricing/access assumptions and regional launch requirements.
• Corporate: cap table, program budget, existing alliances, change-of-control terms and a complete schedule of third-party obligations.

IP and freedom-to-operate risk

Map composition-of-matter, target-mechanism, formulation and use claims around NS5A; confirm assignments and territory coverage. The scan does not substitute for claim-chart analysis. Diligence should reconcile patent-family ownership, inventorship, priority support, prosecution status, expiry and patent-term adjustment, licenses, government funding, employee/consultant assignments, oppositions and litigation. Separate platform blocking risk from asset-specific composition, use, dosing, formulation and manufacturing risk.

Deal precedent and transaction framing

• 歌禮宣佈和輝瑞就新冠藥物PAXLOVID™簽訂中國大陸利托那韋授權與供應協議 (2022-10-28). Economics were not disclosed in the returned record.

Use returned transactions as negotiation anchors only after normalizing modality, stage at signing, territory, option structure, cost sharing and development obligations. Where no directly comparable precedent is returned, construct a broader target-, modality- and indication-level set before proposing economics.

Financial signals

• Ascletis Pharma Inc. - 财务资料: Ascletis Pharma Inc. - 财务资料 影响我们经营业绩的主要因素 我们认为，影响我们经营业绩、财务状况及现金流量的主要因素包括： ‧ 我们在研药物的商业化。于二零一六年及二零一七年，我们分别录得亏损净额人 民币6.8 百万元及人民币131.8 百万元，因为我们并无于该等期间产生来自产品销 售的收益。我们预期于二零一八年第三季前将戈诺卫®商业化并开始自产品销售产 生收益。我们亦预计于未来数年将其他产品（包括拉维达韦）商业化。 ‧ 研发开支。于二零一七年，我们的研发开支较二零一六年增加人民币51.6 百万 元，主要与开发拉维达韦等在研药物所产生的临床试验成本及员工成本增加有 关。我们的研发开支受我们现有产品管线的时间及进展以及启动新药计划的时间 及数量所影响。 ‧…
• Ascletis Pharma Inc. - 概要: Ascletis Pharma Inc. - 概要 业务策略 我们拟实施以下方面的业务策略：(i) 提高戈诺卫® 的销售额；(ii) 利用我们的戈诺卫® 经验来实现拉维达韦的商业化；(iii) 提高患者意识及教育，以增加丙肝治疗需求；(iv) 发展 和巩固抗病毒渠道；及(v) 发挥和加强我们的平台优势，进一步寻求许可及收购机会。请参 阅「业务－业务策略」。 关键财务资料概要 下文所载财务资料历史数据概要乃摘录自本文件附录一会计师报告所载综合经审核财 务报表（包括相关附注）以及本文件「财务资料」所载资料并应与该等资料一并阅读。我们的 财务资料乃根据香港财务报告准则编制。 综合损益表数据概要 于截至2016 年及2017 年12 月31 日止两个年度，我们并无将任何产品商业化，因此并…

Financial-report passages are outreach signals rather than a valuation model. Translate them into questions about runway, program prioritization, non-dilutive capital needs, development-cost sharing and willingness to trade territory for funding or capabilities.

Recent events and timing clues

• Current Awareness MCP did not return a company-specific recent event for this query. Confirm material events, trial changes, financing and partnering activity through current disclosures.

Reconfirm every time-sensitive event before contact. The strongest outreach window is normally just before a financing, data readout, regulator interaction, indication expansion or manufacturing commitment—when a partner can change the risk or capital profile.

Recommended outreach sequence

1. Confirm ownership: contact business development and legal with a one-page statement of interest naming Ravidasvir Hydrochloride, territory and proposed collaboration type.
2. Request a staged data room: begin with non-confidential evidence, then gate patient-level, CMC and IP materials under NDA.
3. Offer a specific value exchange: link capital, development execution, regulatory access, manufacturing or commercialization reach to the owner’s next milestone.
4. Propose structure: compare regional license, option-to-license, co-development and asset acquisition pathways with explicit decision points.
5. Define stop/go criteria: ownership defects, unsupported differentiation, unmanageable safety/CMC risk or blocking IP should pause valuation work.

Decision gates for the partnering team

Advance the opportunity only when four gates can be answered with traceable evidence. First, the legal owner must control the asset and the rights under discussion. Second, the next development milestone must be supported by a coherent clinical, translational and CMC package. Third, the proposed partner must contribute a capability that changes probability, timing, cost or commercial reach rather than merely adding capital. Fourth, the transaction must remain attractive after probability adjustment, remaining development spend, competitive displacement and third-party obligations.

At the initial screen, classify each gate as supported, unresolved or adverse. Unresolved items become dated data-room requests with a named owner; adverse items require a mitigation plan and explicit valuation effect. This discipline keeps early enthusiasm from turning missing evidence into an implicit positive assumption and gives both parties a clear path from introductory outreach to diligence, governance design and executable economics.

BD conclusion

Ascletis Pharmaceuticals Co., Ltd. merits a targeted, evidence-gated outreach centered on Ravidasvir Hydrochloride and its reported Approved status. The initial objective is not to negotiate headline economics; it is to resolve current ownership, evidence readiness, strategic fit and rights availability. A successful first interaction should produce a clean owner map, milestone calendar, diligence index and agreed pathway to a term-sheet discussion.

Build your next partnering scan with PatSnap MCP. Connect pipeline, transaction, financial and current-awareness evidence through the PatSnap MCP server marketplace.